Diagnosis Value of SEMA4C in Breast Cancer
Maneno muhimu
Kikemikali
Maelezo
Breast cancer remains the most common cancer in women worldwide, with approximately 1.68 million new cases, and 0.52 million deaths, annually. Meanwhile the incidence of breast cancer continues to increase. Early diagnosis and access to optimum treatment are crucial to reduce mortality associated with breast cancer. Currently, mammography and breast ultrasonography are essential for the detection and diagnosis of disease, and breast magnetic resonance imaging is the choice to estimate the extent of disease and guide appropriate treatment. However, there is no robust biomarkers for early detection of breast cancer.
Semaphorin4C (SEMA4C) has been previously identified as a highly expressed protein by breast cancer-associated lymphatic endothelial cells (LECs) using in situ laser capture microdissection of lymphatic vessels, followed by cDNA microarray analysis. Moreover, membrane-bound SEMA4C is cleaved by matrix metalloproteinase (MMPs) to release a soluble form of this protein. Therefore, this prospective project aims to assess the early diagnostic value of SEMA4C as a biomarker for breast cancer.
Tarehe
| Imethibitishwa Mwisho: | 08/31/2018 |
| Iliyowasilishwa Kwanza: | 09/02/2018 |
| Uandikishaji uliokadiriwa Uliwasilishwa: | 09/04/2018 |
| Iliyotumwa Kwanza: | 09/06/2018 |
| Sasisho la Mwisho Liliwasilishwa: | 09/04/2018 |
| Sasisho la Mwisho Lilichapishwa: | 09/06/2018 |
| Tarehe halisi ya kuanza kwa masomo: | 08/31/2019 |
| Tarehe ya Kukamilisha Msingi iliyokadiriwa: | 08/31/2021 |
| Tarehe ya Kukamilisha Utafiti: | 08/31/2024 |
Hali au ugonjwa
Uingiliaji / matibabu
Diagnostic Test: Breast cancer group
Diagnostic Test: Benign breast tumor group
Awamu
Vikundi vya Arm
| Mkono | Uingiliaji / matibabu |
|---|---|
| Breast cancer group Patients who have histologically confirmed new diagnosis of breast cancer are recruited. | Diagnostic Test: Breast cancer group All the serum samples are collected before any treatments and will be tested in single center in order to decrease bias. Serum SEMA4C levels were measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits. |
| Benign breast tumor group Patients who have histologically confirmed new diagnosis of benign breast tumors are recruited. | Diagnostic Test: Benign breast tumor group All the serum samples are collected before any treatments and will be tested in single center in order to decrease bias. Serum SEMA4C levels were measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits. |
Vigezo vya Kustahiki
| Zama zinazostahiki Kujifunza | 18 Years Kwa 18 Years |
| Jinsia Inastahiki Kujifunza | Female |
| Njia ya sampuli | Non-Probability Sample |
| Hupokea Wajitolea wa Afya | Ndio |
| Vigezo | Inclusion Criteria: - Receiving no treatment before diagnosis - Establishing Diagnosis according to biopsy or surgery Exclusion Criteria: - Patients who are not mentally capable of giving written informed consent - Clinical data missing - Serum samples doesn't qualified - Patients with a diagnosis of other severe acute or chronic medical conditions that may interfere with the interpretation of the study results |
Matokeo
Hatua za Matokeo ya Msingi
1. Diagnostic potential of SEMA4C as a biomarker for breast cancer [At the time of inclusion]
Hatua za Matokeo ya Sekondari
1. Serum SEMA4C, Mammography, breast US and MRI in comparison and combination to distinguish breast cancer from benign breast tumor [At the time of inclusion]
